Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference


Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 at 10:00am ET/7:00am PT. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).


These press releases may also interest you

at 22:34
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
Cynata Therapeutics Limited , a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key Highlights The trial met its primary...

at 21:44
Leqembi® approved in Mexico
BioArctic AB's (publ) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.   Leqembi...

at 20:20
dBio joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
dBio has joined the American Heart Association Center for Health Technology & Innovation (the Center) Innovators' Network, an initiative focused on building and fostering health technology relationships to develop innovative and scalable...

at 20:05
Entrepreneurs from Asian Countries and Regions Compete at AEA2024 Innovation Award held in Kashiwa-no-ha
The Asian Entrepreneurship Award (AEA) Steering Committee is pleased to announce that AEA2024, the 13th annual innovation award event for fast-growing Asian startups, was held on November 20th and 21st. Taking place in-person for the first time in...

at 18:40
Tomorrow's Promise, Today's Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment
Roswell Park CEO Candace S. Johnson, PhD, introduces center's first Physician in Chief, leaders in strategic areas Michael Wong, MD, PhD, FRPC, joins Roswell Park from MD Anderson...

at 18:31
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta...

More news about Health...


News published on and distributed by: